Edaravone for treating amyotrophic lateral sclerosis

Daily oral edaravone is currently in clinical development for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease (MND). ALS is a rare, life-limiting disease that causes the deterioration of nerve cells in the brain and spinal cord, which control voluntary movements such as walking and breathing. The gradual decline of nerve cells causes a loss of muscle function, difficulty moving and eventually paralysis, problems breathing without ventilatory support and death. There is a lack of effective treatments for ALS.